A phase 1/2 study of the TORC1/2 inhibitor onatasertib combined with toripalimab in patients with advanced solid tumors: Cervical cancer cohort

被引：0
|
作者：
Yuan, Li
Shu, Pei
Li, Xiaoyu
Li, Guiling
Zhang, Keqiang
Lai, Lin
Hong, Jinsheng
Huang, Chu-Ying
Wang, Yongsheng
Xie, Hui
Zheng, Li
Zhou, Qi
机构：
[1] Chongqing Univ Canc Hosp, Chongqing, Peoples R China
[2] Sichuan Univ, West China Hosp, Natl Med Prod Adm Key Lab Clin Res & Evaluat Inno, Clin Trial Ctr,State Key Lab Biotherapy, Chengdu, Peoples R China
[3] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Wuhan, Peoples R China
[4] Hunan Canc Hosp, Changsha, Peoples R China
[5] Cent Hosp Enshi Tujia & Miao Autonomous Prefectur, Dept Abdominal Oncol, Enshi, Peoples R China
[6] Fujian Med Univ, Dept Radiotherapy, Ctr Canc, Affiliated Hosp 1, Fuzhou, Peoples R China
[7] Hubei Selenium & Human Hlth Inst, Cent Hosp Enshi Tujia & Miao Autonomous Prefectur, Enshi, Peoples R China
[8] Sichuan Univ, West China Hosp, Chengdu, Peoples R China
[9] Antengene Corp, Dept Clin Res & Dev, Shanghai, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5509
引用
收藏
页数：1
相关论文
共 50 条
  • [1] A phase 1/2 study of the TORC1/2 inhibitor onatasertib combined with toripalimab in patients with advanced solid tumors
    Shu, Pei
    Li, Xiaoyu
    Yuan, Li
    Zhou, Qi
    Li, Guiling
    Zhang, Keqiang
    Xie, Hui
    Wang, Yongsheng
    Li, Qiu
    Zheng, Li
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [2] A phase 1/2 study of onatasertib, a dual TORC1/2 inhibitor, combined with the PD-1 antibody toripalimab in patients with advanced solid tumors (TORCH-2)
    Shu, Pei
    Li, Xiaoyu
    Yuan, Li
    Xie, Hui
    Zhou, Qi
    Wang, Yongsheng
    Li, Qiu
    Zheng, Li
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [3] A Phase Ib Expansion Cohort Evaluating Aurora A Kinase Inhibitor Alisertib and Dual TORC1/2 Inhibitor Sapanisertib in Patients with Advanced Solid Tumors
    Davis, S. Lindsey
    Messersmith, Wells A.
    Purcell, W. Thomas
    Lam, Elaine T.
    Corr, Bradley R.
    Leal, Alexis D.
    Lieu, Christopher H.
    O'Bryant, Cindy L.
    Smoots, Stephen G.
    Dus, Evan D.
    Jordan, Kimberly R.
    Serkova, Natalie J.
    Pitts, Todd M.
    Diamond, Jennifer R.
    CANCERS, 2024, 16 (08)
  • [4] Phase I expansion trial of an oral TORC1/TORC2 inhibitor (CC-223) in advanced solid tumors.
    Varga, Andrea
    Mita, Monica M.
    Wu, Jennifer J.
    Nemunaitis, John J.
    Cloughesy, Timothy Francis
    Mischel, Paul S.
    Bendell, Johanna C.
    Shih, Kent C.
    Paz-Ares, Luis G.
    Mahipal, Amit
    Delord, Jean-Pierre
    Kelley, Robin Katie
    Soria, Jean-Charles
    Wong, Lilly
    Xu, Shuichan
    James, Angela
    Wu, Xiaoling
    Chopra, Rajesh
    Hege, Kristen
    Munster, Pamela N.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [5] A phase Ib study of the combination of alisertib (Aurora A kinase inhibitor) and MLN0128 (dual TORC1/2 Inhibitor) in patients with advanced solid tumors, final expansion cohort data.
    Davis, S. Lindsey
    Leal, Alexis Diane
    Messersmith, Wells A.
    Lieu, Christopher Hanyoung
    Lam, Elaine T.
    Corr, Bradley
    O'Bryant, Cindy L.
    Serkova, Natalie Julie
    Pitts, Todd
    Diamond, Jennifer Robinson
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [6] A phase Ib study of the combination of MLN0128 (dual TORC1/2 inhibitor) and MLN8237 (Aurora A inhibitor, alisertib) in patients with advanced solid tumors, expansion cohort data
    Davis, S. L.
    Leong, S.
    Messersmith, W.
    Purcell, T.
    Lam, E.
    Corr, B.
    Leal, A.
    O'bryant, C.
    Glode, A.
    Adler, N.
    Serkova, N.
    Diamond, J.
    EUROPEAN JOURNAL OF CANCER, 2018, 103 : E142 - E142
  • [7] A phase 1b study of the combination of MLN0128 (dual TORC1/2 inhibitor) and MLN8237 (Aurora A inhibitor, alisertib) in patients with advanced solid tumors
    Davis, S. Lindsey
    Lam, Elaine T.
    Corr, Bradley R.
    O'Bryant, Cindy L.
    Glode, Ashley
    Adler, Nichole
    Pitts, Todd M.
    Tentler, John J.
    Capasso, Anna
    Dailey, Kyrie
    Serkova, Natalie J.
    Weekes, Colin D.
    Gustafson, Daniel L.
    Lieu, Christopher H.
    Messersmith, Wells A.
    Leong, Stephen
    Eckhardt, S. Gail
    Diamond, Jennifer R.
    MOLECULAR CANCER THERAPEUTICS, 2018, 17 (01)
  • [8] A first-in-human Phase I study of DS-3078a, an oral TORC1/2 inhibitor, in patients with advanced solid tumors: Preliminary results.
    Capelan, Marta
    Kumar, Prasana
    Tolcher, Anthony W.
    Zivi, Andrea
    Desai, Madhuri
    Papadopoulos, Kyriakos P.
    Senaldi, Giorgio
    Patnaik, Amita
    Banerji, Udai
    Rasco, Drew D.
    MOLECULAR CANCER THERAPEUTICS, 2013, 12 (11)
  • [9] Phase I trial of an oral TORC1/TORC2 inhibitor (CC-223) in advanced solid and hematologic cancers.
    Shih, Kent C.
    Bendell, Johanna C.
    Reinert, Anne
    Jones, Suzanne
    Kelley, Robin Katie
    Infante, Jeffrey R.
    Korn, Michael
    Hege, Kristen
    Chopra, Rajesh
    Xu, Shuichan
    Wong, Lilly
    Liu, Yong
    Mortensen, Deborah
    Munster, Pamela N.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [10] First-in-human phase I study exploring three schedules of OSI-027, a novel small molecule TORC1/TORC2 inhibitor, in patients with advanced solid tumors and lymphoma
    Tan, D. S.
    Dumez, H.
    Olmos, D.
    Sandhu, S. K.
    Hoeben, A.
    Stephens, A. W.
    Poondru, S.
    Gedrich, R.
    Kaye, S. B.
    Schoffski, P.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
12345